在人类癌症中,RNF213控制着不同的瘤-免疫动态:免疫疗法分层的预后生物标志物

相关实验视频

Updated: Sep 14, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Jinpeng Wen^1,2, Zhekuan Lv^1,3, Mojiao Lu^1,3

¹Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.

Discover oncology

|July 23, 2025

概括

RNF213,一个E3泛素酶,在癌症中表现多种多样的表达,并影响生存率. 高RNF213表达可能预测更好的免疫治疗反应,表明其作为生物标志物的作用.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

RNF213 是一个大型E3泛基因酶,参与DNA修复和免疫.
它在癌症生物学中的作用尚不清楚,尽管在莫亚莫亚病方面进行了广泛的研究.

研究的目的:

进行RNF213表达和突变的泛癌分析.
评估RNF213与临床结果的相关性及其作为预后生物标志物的潜力.
研究RNF213的治疗潜力,特别是在免疫治疗中.

主要方法:

利用了癌症基因组图谱 (TCGA) 和其他公共数据集.
分析了RNF213表达模式,突变频率和临床结果相关性.
对RNF213表达和免疫检查点阻塞疗法的疗效进行了生存分析.

主要成果:

在不同癌症类型中,RNF213的表达有显著的差异 (在质母细胞瘤中表达过度,在肺腺癌中表达不足).
升高的RNF213与急性髓性白血病和低度质瘤的存活率差相关,但在肉瘤和黑色素瘤中存活率更好.
RNF213的表达与免疫基因和细胞透有关,特别是在质母细胞瘤和乳腺癌中.
高RNF213表达预测了抗PD-1和抗CTLA-4联合免疫疗法改善的生存率.

结论:

在瘤进展和免疫调节方面,RNF213表现出双重作用.
作为预后生物标志物和癌症治疗点,RNF213显示出有前途.
RNF213可能对预测免疫治疗结果至关重要,需要进一步的机制研究.

关键词:

免疫检查站封锁免疫检查站封锁免疫治疗是一种免疫疗法.泛癌分析泛癌分析预测生物标志物预测生物标志物 RNF213 是一个字.瘤微环境是一个微环境.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...